NP568793.RASouo1Fh xiRITdyXAFdWspcegCW-Zx54JVHP-y6eLUw
has assertion: NP568793.RASouo1Fh xiRITdyXAFdWspcegCW-Zx54JVHP-y6eLUw130 assertion
has provenance: NP568793.RASouo1Fh xiRITdyXAFdWspcegCW-Zx54JVHP-y6eLUw130 provenance
has publication info: NP568793.RASouo1Fh xiRITdyXAFdWspcegCW-Zx54JVHP-y6eLUw130 publicationInfo
type: Nanopublication
created: 2014-10-02T12:37:43+02:00
rights: http://opendatacommons.org/licenses/odbl/1.0/
rights holder: IBIGroup
subject: SIO_000983
used data: disgenetrdf
authored by: http://orcid.org/0000-0001-5999-6269
authored by: http://orcid.org/0000-0002-7534-7661
authored by: 0000-0002-9383-528X
authored by: http://orcid.org/0000-0003-0169-8159
authored by: http://orcid.org/0000-0003-1244-7654
created by: http://orcid.org/0000-0003-0169-8159
version: v2.1.0.0

NP568793.RASouo1Fh xiRITdyXAFdWspcegCW-Zx54JVHP-y6eLUw130 assertion
type: Assertion
description: [VEGFR1, TGFBR1, PDGFRA, SSTR5, SSTR2A, and IGF1R exhibited the highest levels of expression in the largest percentages of PETs.Anticancer drugs BMS-754807 (selective for IGF1R/IR), 17-(allylamino)-17-demethoxygeldanamycin (17-AAG, targeting Hsp90), and axitinib (directed toward VEGFR1-3/PDGFRA-B/KIT) induced growth inhibition of human QGP-1 PET cells with IC50 values (nM) of 273, 723, and 743, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
evidence: DisGeNET evidence - LITERATURE
SIO_000772: http://identifiers.org/pubmed/23211371
was generated by: ECO_0000203

befree-20140225
imported on: 2014-02-25

DisGeNET evidence - LITERATURE
type: ECO_0000212
comment: Gene-disease associations inferred from text-mining the literature.

disgenetrdf
version: v2.1.0